Last reviewed · How we verify

ezetimibe with simvastatin — Competitive Intelligence Brief

ezetimibe with simvastatin (ezetimibe with simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholesterol absorption inhibitor and statin. Area: Cardiovascular.

phase 3 Cholesterol absorption inhibitor and statin NPC1L1 and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ezetimibe with simvastatin (ezetimibe with simvastatin) — Organon and Co. Ezetimibe inhibits the absorption of cholesterol in the small intestine, while simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ezetimibe with simvastatin TARGET ezetimibe with simvastatin Organon and Co phase 3 Cholesterol absorption inhibitor and statin NPC1L1 and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholesterol absorption inhibitor and statin class)

  1. Organon and Co · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ezetimibe with simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/ezetimibe-with-simvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: